Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer

PURPOSE: To compare the cost-effectiveness of the tumor subtyping assays Mammostrat® and Oncotype DX® for assessing risk of recurrence in early-stage breast cancer and the potential benefit of adjuvant chemotherapy. METHODS: Cost-effectiveness analysis from a US third-party payer perspective. A 10 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Mislick, Kimberly, Schonfeld, Warren, Bodnar, Carolyn, Tong, Kuo Bianchini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896273/
https://www.ncbi.nlm.nih.gov/pubmed/24470765
http://dx.doi.org/10.2147/CEOR.S53142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896273/
https://www.ncbi.nlm.nih.gov/pubmed/24470765
http://dx.doi.org/10.2147/CEOR.S53142

Ejemplares similares